Abstract: The present invention provides methods and compositions that use the combination of Tris and EDTA to inhibit the growth of microorganisms at the site of a wound or burn, and/or to promote the healing of a wound or burn, and/or to reduce the sensation of pain at the site of a wound or burn. The amount of Tris and EDTA applied to a wound or burn can be selected to achieve one or more of the foregoing effects.

Abstract: The present invention provides methods and compositions that use the combination of Tris and EDTA to inhibit the growth of microorganisms at the site of a wound or burn, and/or to promote the healing of a wound or burn, and/or to reduce the sensation of pain at the site of a wound or burn. The amount of Tris and EDTA applied to a wound or burn can be selected to achieve one or more of the foregoing effects.

Abstract: The present invention provides methods and compositions that use the combination of Tris and EDTA to inhibit the growth of microorganisms at the site of a wound or burn, and/or to promote the healing of a wound or burn, and/or to reduce the sensation of pain at the site of a wound or burn. The amount of Tris and EDTA applied to a wound or burn can be selected to achieve one or more of the foregoing effects.

Abstract: The present invention provides methods and compositions that use the combination of Tris and EDTA to inhibit the growth of microorganisms at the site of a wound or burn, and/or to promote the healing of a wound or burn, and/or to reduce the sensation of pain at the site of a wound or burn. The amount of Tris and EDTA applied to a wound or burn can be selected to achieve one or more of the foregoing effects.

Abstract: The present invention provides methods and compositions that use the combination of Tris and EDTA to inhibit the growth of microorganisms at the site of a wound or burn, and/or to promote the healing of a wound or burn, and/or to reduce the sensation of pain at the site of a wound or burn. The amount of Tris and EDTA applied to a wound or burn can be selected to achieve one or more of the foregoing effects.

Abstract: The present invention provides methods and compositions that use the combination of Tris and EDTA to inhibit the growth of microorganisms at the site of a wound or burn, and/or to promote the healing of a wound or burn, and/or to reduce the sensation of pain at the site of a wound or burn. The amount of Tris and EDTA applied to a wound or burn can be selected to achieve one or more of the foregoing effects.

Abstract: The present invention provides methods and compositions for use in the methods for contacting an eye of a patient with an effective amount of therapeutic composition comprising a pharmaceutically acceptable chelating agent, a pharmaceutically acceptable pH buffering agent, and an antimicrobial agent.

Abstract: The present invention provides methods for the detection of biliverdin in birds (avian species) and reptiles.

Abstract: The present invention provides a skin cleanser comprising a chelating agent, a buffering agent, a carrier and a detergent such as cocamidopropyl betaine and at concentrations that avoid substantial irritation of the skin while having the ability to cleanse the skin surface of contaminants. The compositions are especially useful to cleanse the external ear canal of an animal. The chelating agent has a synergistic effect on the ability of the detergent to loosen cerumen and other contaminants from the skin surface, and also on the antimicrobial and antifungal activity of the detergent, thereby reducing microbial colonization that may develop into a pathological condition if not treated. The present invention provides methods for cleansing a skin surface by using the ccleanser which may include more than one antimicrobial agent to inhibit the proliferation of a single invasive organism, or a mixed population of invasive organisms.

Abstract: The present invention provides methods for wound management that comprise contacting a wound of a patient with an effective amount of a therapeutic composition comprising a chelating agent, a pH buffering agent, an antimicrobial agent, Vitamin E and a carrier and a surfactant. The antimicrobial agent(s) has increased antimicrobial activity because of the synergy with the chelating agent and maintenance of the treated area at a pH suitable for sustained antibiotic activity so that the antimicrobial agent can be used in effective doses that are less than in the absence of the chelator. The Vitamin E promotes tissue repair, reducing the likelihood of opportunistic infection, improving wound healing and reducing pain sensation. The wound management methods of the present invention further include contacting the wound with a medical dressing having an effective amount of the composition deposited thereon.

Abstract: The present invention relates to novel method of reducing microbial infections, especially bacterial infections, of animals, especially of aquatic animals such as fish maintained in tanks or aquaria. The present invention provides bathing and dipping methods for reducing a microbial infection of an animal with an antibiotic solution of enhanced antimicrobial activity comprising at least one chelating agent and at least one antibiotic effective against the microbial infection. The present invention also provides a method for reducing a microbial infection of an animal comprising bathing or dipping an animal having a microbial infection in an antimicrobial solution comprising the chelating agent EDTA, and at least one antibiotic, and optionally a pH buffering agent. The immersion of the aquatic animal in the antimicrobial solution containing the EDTA, antibiotic and pH buffering agent may be repeated until the microbial burden of the animal is eliminated.

Abstract: The invention provides a nucleic acid vaccine which is protective against avian polyomavirus infection in a bird which is classified as being a member of the Psittaciformes order comprising a nucleic acid vaccine vector comprising a suitable eukaryotic cis-acting transcription/translation regulatory sequence functionally linked to a nucleic acid encoding an immunogenic avian polyomarvirus polypeptide. Methods for preventing avian polyomarvirus infection in a bird classified as being a member of the Psittaciformes order, are also provided.

Abstract: The present invention relates to novel method of reducing microbial infections, especially bacterial infections, of animals, especially of aquatic animals such as fish maintained in tanks or aquaria. The present invention provides bathing and dipping methods for reducing a microbial infection of an animal with an antibiotic solution of enhanced antimicrobial activity comprising at least one chelating agent and at least one antibiotic effective against the microbial infection. The present invention also provides a method for reducing a microbial infection of an animal comprising bathing or dipping an animal having a microbial infection in an antimicrobial solution comprising the chelating agent EDTA, and at least one antibiotic, and optionally a pH buffering agent. The immersion of the aquatic animal in the antimicrobial solution containing the EDTA, antibiotic and pH buffering agent may be repeated until the microbial burden of the animal is eliminated.

Abstract: The present invention relates to methods of inhibiting the proliferation of a microbial population of a surface lesion of a human or animal, wherein the lesion is contacted with an antimicrobial composition comprising a pharmaceutically acceptable antibiotic, a pharmaceutically acceptable chelating agent and a pharmaceutically acceptable pH buffering agent. Another aspect of the present invention is a medical dressing for delivering an antimicrobial composition to a site of a skin injury or lesion of a mammal, comprising a support and an antimicrobial composition, wherein the antimicrobial composition is at least one antimicrobial agent and at least one chelating agent. The present invention also relates to methods for delivering an antibiotic to an injury to the skin of a human or animal and to kits for the preparation and use of an antimicrobial composition to inhibit a microbial infection of a skin injury or lesion of a human or animal.

Abstract: Vaccine compositions which are protective against circovirus infections, including porcine circovirus and psittacine beak and feather disease virus, in animals, comprising a nucleic acid vector comprising a eukaryotic cis-acting transcription/translation regulatory sequence functionally linked to a nucleic acid encoding an animal circovirus polypeptide, wherein the nucleic acid lacks a viral origin of replication are disclosed. Nucleic acid vectors for the transient expression of one or more circovirus polypeptides in a eukaryotic cell comprising a nucleic acid vector comprising a eukaryotic cis-acting transcription/translation regulatory sequence functionally linked to the nucleic acids of the invention are described.

Abstract: The present invention provides a vaccine which is protective against avian polyomavirus infection in a bird which is classified as being a member of the Psittaciformes order which comprises an immunogenic amount of a modified live avian polyomavirus in a pharmaceutically acceptable carrier. Methods are also provided for preventing avian polyomavirus infection in a bird, or in several different species of birds, classified as being a member of the Psittaciformes order, comprising administering a vaccine comprising an immunogenic amount of a modified live avian polyomavirus and a pharmaceutically acceptable carrier. A preferred embodiment provides a modified live avian polyomavirus vaccine for prevention of wild-type infection in a Budgerigar, lovebird or Cockatiel.

Abstract: The present invention provides a vaccine which is protective against avian polyomavirus infection in a bird which is classified as being a member of the Psittaciformes order which comprises an immunogenic amount of an inactivated avian polyomavirus in a pharmaceutically acceptable carrier. Also provided is a vaccine which is protective against avian polyomavirus infection in a bird which is classified as being a member of the Psittaciformes order, comprising an immunogenic amount of a recombinant protein derived from an avian polyomavirus and a pharmaceutically acceptable carrier. Also provided is an adjuvant suitable for use in a bird which is classified as being a member of the Psittaciformes order. Further provided is a composition which produces an anamnestic response against avian polyomavirus infection in a sensitized bird which is classified as being a member of the Psittaciformes order, which comprises an anamnestic response inducing amount of a recombinant protein (e.g.

Abstract: The present invention provides a vaccine which is protective against avian polyomavirus infection in a bird which is classified as being a member of the Psittaciformes order which comprises an immunogenic amount of an inactivated avian polyomavirus in a pharmaceutically acceptable carrier. Also provided is an adjuvant suitable for use in a bird which is classified as being a member of the Psittaciformes order. Further provided is a composition which produces an anamnestic response against avian polyomavirus infection in a sensitized bird which is classified as being a member of the Psittaciformes order, which comprises an anamnestic response inducing amount of a recombinant protein (e.g., VP1 capsid protein) of avian polyomavirus in a pharmaceutically acceptable carrier.